The Molecular and Cellular Basis for Parkinson's Disease
The focus on dopamine-sensitive motor symptoms, in association with the improvement of motor complications in the heterogeneous disease entity Parkinson's disease, has led to a certain standstill in research. This Special Issue provides new concepts and new ideas on the pathogenesis, genetics,...
Saved in:
| Main Author: | |
|---|---|
| Format: | Electronic Book Chapter |
| Language: | English |
| Published: |
MDPI - Multidisciplinary Digital Publishing Institute
2019
|
| Subjects: | |
| Online Access: | DOAB: download the publication DOAB: description of the publication |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000naaaa2200000uu 4500 | ||
|---|---|---|---|
| 001 | doab_20_500_12854_53820 | ||
| 005 | 20210211 | ||
| 003 | oapen | ||
| 006 | m o d | ||
| 007 | cr|mn|---annan | ||
| 008 | 20210211s2019 xx |||||o ||| 0|eng d | ||
| 020 | |a books978-3-03921-549-2 | ||
| 020 | |a 9783039215492 | ||
| 020 | |a 9783039215485 | ||
| 040 | |a oapen |c oapen | ||
| 024 | 7 | |a 10.3390/books978-3-03921-549-2 |c doi | |
| 041 | 0 | |a eng | |
| 042 | |a dc | ||
| 072 | 7 | |a M |2 bicssc | |
| 100 | 1 | |a Müller, Thomas |4 auth | |
| 245 | 1 | 0 | |a The Molecular and Cellular Basis for Parkinson's Disease |
| 260 | |b MDPI - Multidisciplinary Digital Publishing Institute |c 2019 | ||
| 300 | |a 1 electronic resource (230 p.) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 506 | 0 | |a Open Access |2 star |f Unrestricted online access | |
| 520 | |a The focus on dopamine-sensitive motor symptoms, in association with the improvement of motor complications in the heterogeneous disease entity Parkinson's disease, has led to a certain standstill in research. This Special Issue provides new concepts and new ideas on the pathogenesis, genetics, and clinical maintenance of Parkinson's disease and related disorders. Not only new experimental findings, but also clinical outcomes, case series, and research on alternative, non-pharmacological therapies are included. The objective is to bridge the currently increasing gap between experimental and clinical research on Parkinson's disease and related disorders. | ||
| 540 | |a Creative Commons |f https://creativecommons.org/licenses/by-nc-nd/4.0/ |2 cc |4 https://creativecommons.org/licenses/by-nc-nd/4.0/ | ||
| 546 | |a English | ||
| 650 | 7 | |a Medicine |2 bicssc | |
| 653 | |a microRNAs | ||
| 653 | |a disease-modifying effects | ||
| 653 | |a SH-SY5Y | ||
| 653 | |a inpatient treatment | ||
| 653 | |a sphingolipids | ||
| 653 | |a neurodegeneration | ||
| 653 | |a magnetic resonance spectroscopy | ||
| 653 | |a MO3.13 | ||
| 653 | |a schizophrenia | ||
| 653 | |a epigenetics | ||
| 653 | |a long-chain acylcarnitine | ||
| 653 | |a molecular mimicry | ||
| 653 | |a curli | ||
| 653 | |a multimodal complex treatment | ||
| 653 | |a chlorogenic acid | ||
| 653 | |a glycerophospholipids | ||
| 653 | |a caffeic acid | ||
| 653 | |a lipoproteins | ||
| 653 | |a myenteric plexus | ||
| 653 | |a neurometabolites | ||
| 653 | |a HOG | ||
| 653 | |a immature oligodendrocyte | ||
| 653 | |a autophagy | ||
| 653 | |a oligodendrocyte | ||
| 653 | |a hypochlorite | ||
| 653 | |a alpha-synuclein | ||
| 653 | |a microbiome | ||
| 653 | |a glucocerebrosidase | ||
| 653 | |a Lewy Body Dementia | ||
| 653 | |a brain iron | ||
| 653 | |a mesenchymal stem cells | ||
| 653 | |a fatty acid ?-oxidation | ||
| 653 | |a GABA | ||
| 653 | |a enteric glial cell | ||
| 653 | |a gut-brain axis | ||
| 653 | |a microbiota | ||
| 653 | |a REM sleep behavior disorders | ||
| 653 | |a redox cycling | ||
| 653 | |a magnetic resonance imaging | ||
| 653 | |a differentiation | ||
| 653 | |a ?-synuclein-mediated pathology | ||
| 653 | |a Parkinson disease | ||
| 653 | |a Gaucher's disease | ||
| 653 | |a metallothionein | ||
| 653 | |a [123I]FP-CIT-SPECT | ||
| 653 | |a dopaminergic neuron | ||
| 653 | |a mature oligodendrocyte | ||
| 653 | |a glycerolipids | ||
| 653 | |a spectroscopy | ||
| 653 | |a neuroinflammation | ||
| 653 | |a exosomes | ||
| 653 | |a immunotherapy | ||
| 653 | |a DNA methylation | ||
| 653 | |a sterol lipids | ||
| 653 | |a nigral cells | ||
| 653 | |a cell line | ||
| 653 | |a cysteinyl-dopamine | ||
| 653 | |a myelin | ||
| 653 | |a parkinsonisms | ||
| 653 | |a multiple sclerosis | ||
| 653 | |a rotenone | ||
| 653 | |a brain | ||
| 653 | |a fatty acyls | ||
| 653 | |a Krabbe's disease | ||
| 653 | |a neuroprotection | ||
| 653 | |a DAT | ||
| 653 | |a motor dysfunction | ||
| 653 | |a secretome | ||
| 653 | |a multiprofessional therapy | ||
| 653 | |a Parkinson's disease | ||
| 653 | |a oxidative stress | ||
| 653 | |a alpha-Synuclein | ||
| 856 | 4 | 0 | |a www.oapen.org |u https://mdpi.com/books/pdfview/book/1705 |7 0 |z DOAB: download the publication |
| 856 | 4 | 0 | |a www.oapen.org |u https://directory.doabooks.org/handle/20.500.12854/53820 |7 0 |z DOAB: description of the publication |